CSL Seqirus inks fifth contract with BARDA, making the partnership now worth $1.14B

Anna Brown

News Reporter

CSL Seqirus has secured a fresh $121.4 million contract with the US Biomedical Advanced Research and Development Authority to manufacture and supply its adjuvanted vaccine …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

CSL Seqirus inks fifth contract with BARDA, making the partnership now worth $1.14B

Anna Brown

News Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

The Endpoints 11 winners: Big bets on AI, new frontiers in editing, a neuro renaissance and Chinese chemistry

FDA approves Bristol Myers and Karuna's schizophrenia drug, in milestone for psychiatry

Steve Davis leaves Acadia, replaced by Bristol Myers alum; Former J&J exec to lead R&D at Novavax

FDA approves Dupixent in COPD, opening ‘next chapter’ for Sanofi and Regeneron’s bestseller

Cassava and its former execs settle SEC charges for ‘misleading’ Alzheimer’s drug data

PDCs vs. ADCs: A New Frontier in Targeted Cancer Therapies and the Potential for Development Partnerships

CSL Se­qirus inks fifth con­tract with BAR­DA, mak­ing the part­ner­ship now worth $1.14B

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

CSL Seqirus inks fifth contract with BARDA, making the partnership now worth $1.14B